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n	 INTRODUCTION
Systemic sclerosis (SSc) is a connec-tive tissue disease characterized by ab-
normal production of fibrotic tissue in the 
skin and internal organs, and by endothe-
lial dysfunction. The latter leads to a num-
ber of clinical manifestations, from Rayn-
aud’s phenomenon to pulmonary arterial 
hypertension. In this respect, an unbalance 
between vasodilator and vasoconstrictor 
agents secreted by endothelium can be 
evidenced in scleroderma patients (1-3). 
Moreover, a stimulation of both the innate 
and adaptive immune responses coexists, 
resulting in B-cell and T-cell activation 
and, in many cases, autoantibody produc-
tion (1). Inflammation leads to fibroblasts 
activation and to collagen deposition.
A diffuse vascular damage may be easily 
evidenced at capillary loops by means of 
nailfold capillaroscopy, as well as at large 
vessel wall where atherosclerotic changes 
may be shown, regardless the classical 
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summary
Background. Systemic sclerosis (SSc) is characterized by endothelial dysfunction and widespread microan-
giopathy. However, a macrovascular damage could be also associated. Aortic pulse wave velocity (aPWV) is 
known to be a reliable indicator of arterial stiffness and a useful prognostic predictor of cardiovascular events. 
Moreover, aPWV may be easily measured by non-invasive, user-friendly tool. Aim of our study was to evaluate 
aPWV alterations in a series of SSc patients.
Methods. The aPWV was evaluated in 35 consecutive female SSc patients and 26 sex- and age-matched healthy 
controls. aPWV alterations were correlated with cardiopulmonary involvement.
Results. A significant increase of aPWV was observed in SSc patients compared to controls (9.4±3.2 m/s vs 
7.3±1 m/s; P=0.002). In particular, 14/35 (40%) SSc patients and only 1/26 (4%) controls (P=0.0009) showed 
increased aPWV (>9 m/s cut-off value). Moreover, echocardiography evaluation showed an increased preva-
lence of right atrial and ventricular dilatation (atrial volume: 23.6±6.2 mL vs 20.3±4.3 mL, P=0.026; ventricular 
diameter 19.5±4.9 mm vs 15.9±1.6 mm; P=0.001) associated to higher values of pulmonary arterial systolic 
pressure (PAPs) in SSc patients (31.5±10.4 mmHg vs 21.6±2.9 mmHg; P<0.0001; 40% of SSc patients showed 
an abnormal PAPs). Clinically, SSc patients presented a reduction of six-minute walking test (413±96 m vs 
491±49 m; P=0.001), not correlated with pulmonary function tests. Increased aPWV values were evidenced 
only in SSc patients >50 years old. Furthermore, altered aPWV was more frequently associated with limited 
cutaneous pattern, longer disease duration (≥5 years), and/or presence of anticentromere antibody (ACA).
Conclusions. A significantly higher prevalence of abnormally increased aPWV was evidenced in SSc patients 
compared to healthy controls. The possibility of more pronounced and diffuse vascular damage in a particular 
SSc subset (ACA-positive subjects with limited cutaneous scleroderma and longer disease duration) might 
be raised.
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cardiovascular risk factors (4-6). There-
fore, even though SSc was traditionally 
considered a disease involving the micro-
vasculature, many studies have demon-
strated an involvement of the whole vas-
cular system (7-11). 
In particular, an increased arterial wall 
stiffness and an impaired flow mediated 
dilatation have been shown at the carotid 
or brachial arteries (12, 13). Furthermore, 
more recent studies demonstrated a rele-
vant prevalence of autopsy-proven macro-
vascular involvement in SSc patients, oc-
curring in more than a decade earlier than 
the general population (4). 
Currently, several non-invasive tools are 
available in clinical practice in order to 
study the vascular function, among them 
the pulse wave velocity measurement. 
This technique is based on a well-known 
physiologic principle: systolic contraction 
of the left ventricle causes pulse waves 
in the aorta wall, intensified by his elas-
tic medial layer. The waves propagate to 
peripheral vessels through the main aortic 
branches, being reflected at the bifurca-
tions. Therefore, a second reflected wave 
appears as a late systolic peak within the 
sphygmic waveform. The morphology of 
the sphygmic wave depends upon the stiff-
ness of the artery walls (14, 15) since an 
increase in arterial stiffness is related to a 
proportional increase of the velocity of the 
wave propagation. 
According to the classical formula velocity 
= distance/time, aortic pulse wave velocity 
(aPWV) may be easily obtained measuring 
the time of progression of the sphygmic 
wave on the aortic path length. In clinical 
practice, the length between the carotid 
and the femoral pulse locations is used to 
calculate aPWV. Given its high predictive 
value, simplicity, and reproducibility, the 
measurement of aPWV can be considered 
the gold standard in the evaluation of ves-
sel wall elasticity (14, 15). 
Aim of the present study is to evaluate 
aPWV in a series of unselected SSc pa-
tients compared to healthy controls, in or-
der to define the actual prevalence of aortic 
wall stiffness and its possible correlations 
with typical SSc features.
n	 PATIENTS AND METHODS
Patients
Thirty-five unselected female patients fol-
lowed at our Rheumatology Centre and 
affected by SSc (mean age 56.9±12.6SD; 
disease duration 9.6±5.4 SD years) were 
consecutively enrolled in the study from 
January to April 2010. All recruited female 
patients (out of our entire series of 300 SSc) 
were programmed to re-evaluate their heart 
involvement in that time period. Males 
were excluded in order to eliminate gen-
der as confounding factor. All patients met 
the 1980 American College of Rheumatol-
ogy Classification criteria for scleroderma 
(16); their clinico-serological features are 
shown in Table I. A series of 26 sex- and 
age-matched healthy individuals, consecu-
tively evaluated for primary prevention at 
the cardiology unit of our hospital in the 
same period, were used as control group 
(Tab. I). These subjects presented one or 
more cardiovascular risk factor (hyper-
tension, diabetes, hypercholesterolemia, 
smoke, high body mass index, familiarity 
for cardiovascular diseases), but did not 
refer any cardiovascular events previously.
The study was approved by the local ethi-
cal committee and all patients gave their 
consent to participate to the study.
Methods
The aPWV measurement was performed 
in all SSc patients and controls at the time 
of cardiological evaluation. All instrumen-
tal examinations were performed by the 
same trained cardiologist (C.F.). In SSc pa-
tients, cardiologic evaluation was routinely 
performed every year, including physi-
cal examination, ECG, echocardiography 
with pulmonary arterial systolic pressure 
(PAPs) assessment, 6-minutes walking 
test, and pulmonary function tests, includ-
ing the measurement of diffusing capacity 
for carbon monoxide (DLCO) test. More-
over, control subjects underwent a careful 
clinical evaluation at cardiological visit, 
followed by instrumental examinations. 
At the time of the study, urinalysis and 
blood chemistry, including blood cell 
counts, total cholesterol, HDL, triglycer-
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ides, fasting glucose at the morning, cre-
atinine, transaminases, and thyroid stimu-
lating hormone were performed in both 
SSc patients and controls. The 6-minutes 
walking test was performed in a comfort-
able temperature-controlled (22-24°C) in-
door floor, measuring the distance covered 
within 6 minutes, and the oxygen blood 
saturation at baseline and at the end of the 
test by using a handheld pulse oximeter. 
All echocardiograms are performed at the 
echocardiography clinic of our cardiology 
unit, by using a General Electric machine 
(Vivid E). M-Mode, B-Mode, Doppler, and 
Doppler tissue imaging were performed 
according to the guidelines of the Ameri-
can Society of Echocardiography (17). The 
exams included the estimation of PAPs, 
which was based on the peak velocity of 
the tricuspid regurgitation jet, using the 
simplified Bernoulli equation (18). The 
measurement of aPWV was performed in 
the supine position in a quiet, temperature-
controlled room (22-24°C) in the early 
morning hours. Age, body weight, stature, 
and systemic arterial blood pressure, by us-
ing a sphygmomanometer, were previously 
collected. The distance between the carotid 
pulse and the femoral pulse loci was mea-
sured. To determine aPWV, two readings 
at the carotid artery and the femoral artery 
were sequentially obtained by using a to-
nometer (SphygmoCor® VX, AtCor Medi-
cal Pty Ltd., West Ryde, Australia). The 
registered waves were analyzed by an inte-
grated software, and outputted on a laptop 
screen as the corresponding waveforms. A 
rapid sampling of the wave registered was 
automatically done to calculate a quality 
index (%) and to guarantee the intra-/inter-
operator reproducibility. aPWV is obtained 
from the formula velocity = distance/time: 
the distance is the length between the ca-
rotid and the femoral pulse locations, while 
the time is measured by the tonometer.
Besides aPWV measurement, the follow-
ing parameters were obtained: heart rate, 
main diastolic and systolic blood pres-
sure, ejection length of left ventricle, width 
(mmHg) of incident wave, sub-endocardial 
viability ratio, aortic augmentation, and 
augmentation index (adjusted for heart rate 
75 bpm). Among them, the latter is the piv-
otal parameter expressing the stiffness of 
the arterial walls (14). The systolic part of 
the central arterial wave is characterized by 
two pressure peaks, the first one caused by 
left ventricular ejection, while the second 
is the result of the pulse wave reflection. 
The sub-endocardial viability ratio indi-
cates the ratio between availability and re-
quest of energy for the heart to pump. 
Statistical analysis
Values are given as mean±SD for normally 
distributed variables, or as median (range) 
for not-normally distributed variables. To 
compare parameters from SSc patients 
and controls, Student’s t test for normal-
ly distributed and Mann-Whitney u test 
for not normally distributed parameters 
were used. Chi-square with Pearson’s cor-
rection was used for binomial variables, 
while the linear regression was used for 
continuous variables. Fisher’s exact test 
was performed for the statistical analysis 
among the SSc patients, and the multivari-
ate logistic regression analysis was used to 
consider the eventual weight of the single 
scleroderma parameters. A P value ≤0.05 
was considered statistically significant. 
Table I - clinico-serological features and therapies of systemic sclerosis pa-
tients and healthy controls.
ssc patients Healthy controls P value
age (yrs)
Disease duration (yrs)
56.9±12.6
9.6±5.4
56.5±11.7 ns
BMi
Hypertension
Diabetes
Dyslipidemia
cVD familiarity
Smoke history
22.3±3.6
13/35
0/35
8/35
2/35
2/35
25±2.7
15/26
0/26
2/26
7/26
4/26
0.006
ns
ns
ns
0.02
ns
Skin subsets (l/D); (l/i/D)
autoantibodies (Scl70/aca/anoa/ana)
28/7; 22/6/7
13/9/7/5
Digital ulcers 20/35
ca-channel blockers
ace-inhibitors
Sartans
Statins
Diuretics
Beta-antagonists
Prednisone (≤5 mg/day)
24/35
3/35
2/35
5/35
4/35
0/35
12/35
6/26
7/26
5/26
4/26
7/26
5/26
0/26
0.0004
0.056
ns
ns
ns
ns
0.0008
SSc, systemic sclerosis; BMi, body mass index; cVD, cardiovascular diseas-
es; skin subsets: l = limited, i = intermediate, D = diffuse; aca, anticentromere 
antibodies; anoa, anti-nucleolar antibodies; ana, antinuclear antibodies.
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IBM SPSS® (IBM, Armonk, New York, 
USA) software version 17.0 was used for 
statistical analysis.
n	 RESULTS
The aPWV measurements along with car-
diovascular risk factors and echocardiogra-
phy findings in SSc patients are shown in 
Table II. Compared to controls, no differ-
ences about the prevalence of arterial hy-
pertension, diabetes, dyslipidemia, smok-
ing habit, and cardiovascular diseases his-
tory were recorded. On the contrary, a sig-
nificantly higher body mass index (BMI) 
(25±2.7 vs 22.3±3.6; P=0.006), as well as 
a cardiovascular disease familiarity (7/26 
vs 2/35; P=0.02) were observed in controls 
compared to SSc patients. As regards the 
ongoing treatments, only SSc patients were 
taking calcium-channel blockers (24/35) 
and steroids (12/35; average dosage 5 mg/
day of prednisone (for few weeks only), 
while the use of angiotensin converting 
enzyme (ACE) inhibitors, sartans, statins, 
diuretics, and beta-antagonists was com-
parable in the two groups. None of sclero-
derma patients was receiving immunosup-
pressors, endothelin receptor antagonists, 
or phosphodiesterase inhibitors. The values 
of aPWV were statistically higher in SSc 
patients compared to controls (9.4±3.2SD 
vs 7.3±1SD m/s; P=0.002). Considering as 
cut-off 9 m/s (the median value of aPWV 
in scleroderma patients is 8.7 m/s), an ab-
normally high aPWV was detected in 14/35 
(40%) SSc patients and in only 1/26 (4%) 
controls (Fisher’s P=0.0009). The subject 
in the control group with altered PWV (9.1 
m/s) is a 77 year-old female, with hyper-
tension and hypercholesterolemia, and 
BMI 27.6.
The exclusion of SSc patients treated with 
steroids (12 patients) did not change the sta-
tistical difference between the two groups 
(aPWV 9.1±2.7 for SSc vs 7.3±1 for con-
trols; P=0.003; aPWV>cut-off 9m/s: 10/23 
SSc vs 1/26 controls, P=0.001). The echo-
cardiography evidenced several differences 
between SSc patients and controls; namely, 
an increased volume of the right atrium 
(23.6±6.2 mL vs 20.3±4.3 mL; P=0.026) 
and the diameter of the right ventricle 
(19.5±4.9 mm vs 15.9±1.6 mm; P=0.001), 
an augmented prevalence of left ventricle 
hypertrophy (20/35 vs 3/26; P=0.0001), 
and higher values of PAPs (31.5±10.4 
mmHg vs 21.6±2.9 mmHg; P<0.0001). 
Fourteen SSc patients (40%) presented a 
PAPs>35 mmHg. Moreover, evaluating 
the 6-minutes walking test, scleroderma 
patients showed a lower performance com-
pared to controls (413±96SD vs 491±49SD 
m; P=0.001). 
Among SSc patients, few clinico-sero-
logical features correlated with increased 
aPWV (Figs. 1 and 2). Firstly, aPWV 
strictly correlated with the patients’ age, as 
expected (R=0.669; P<0.0001); indeed, all 
patients with abnormally increased aPWV 
were ≥50 years-old. In addition, even 
though a statistical significance was not 
found, SSc patients with longer disease du-
ration tended to present aPWV alterations. 
In particular, abnormal aPWV was almost 
constantly observed in subjects with dis-
ease duration ≥5 years, except for one pa-
tient with recent SSc onset but concomitant 
hypertension and hypercholesterolemia. 
As regards SSc cutaneous subsets, a trend 
(P=ns) to higher percentage of abnormal 
aPWV in limited SSc patients was recorded 
(Fig. 1); namely, considering the LeRoy di-
vision in two patterns (19), the 42% of lim-
ited SSc and the 9% of diffuse SSc patients 
presented abnormally high aPWV values. 
Instead, according to the three-pattern sub-
setting, 50% of limited, 33% of interme-
Table II - instrumental findings in systemic sclerosis patients and healthy con-
trols.
ssc 
patients
Healthy controls P value
aPWV (m/s)
increased aPWV (>9 m/s)
9.4±3.2
14/35
7.3±1
1/26
0.002
0.0009
rV diameter (mm)
PaPs (mmHg)
PaPs ≥35 mmHg
19.4±4.9
31.5±10.4
14/35
15.9±1.6
21.6±2.9
0/26
0.001
<0.0001
0.0001
FVc%
DlcO%
87.3±20.3
47.2±12.2
6-minutes walking test (m) 413±96 491±49 0.0004
SSc, systemic sclerosis; aPWV, aortic pulse wave velocity; rV, right ventricle; 
PaPs, pulmonary arterial systolic pressure; FVc, forced vital capacity; DlcO, 
diffusing capacity for carbon monoxide.
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diate, and 14% of diffuse SSc presented 
increased aPWV. An association between 
aPWV and specific SSc auto-antibodies 
was also found (Fig. 2); namely abnormal-
ly high values of aPWV were detected in 
60% of patients with serum anticentromere 
antibody (ACA), compared to 23% of anti-
Scl70-positive and 43% of antinucleolar-
positive SSc patients (P=ns).
Finally, in SSc patients no correlations 
were found between aPWV alterations and 
presence/absence of digital ulcers, abnor-
mal pulmonary function tests (forced vital 
capacity (FVC) <75% or DLCO<50%), 
abnormal PAPs, presence of cardiovascular 
risk factors (smoking habit, hypertension, 
diabetes, hypercholesterolemia, increased 
BMI), and treatments (ACE inhibitors, 
calcium-channel blockers, statins, steroids, 
and L-thyroxin).
n	 DISCUSSION
The present study demonstrated an ab-
normally increased aPWV in SSc patients 
compared to controls. Besides the expected 
correlation between aPWV increase and 
the patients’ age, a tendency to an associa-
tion between aPWV alteration and limited 
cutaneous pattern of SSc and/or presence 
of circulating ACA was evidenced. The ab-
sence of statistical significance is possibly 
due to the low number of patients in dif-
ferent clinico-serological SSc subgroups. 
In this respect, it is well known that SSc 
patients with serum ACA and/or limited 
cutaneous involvement show an increased 
risk to develop peripheral vasculopathy, 
often complicated by severe digital ulcers 
(20-22). Our findings are consistent with 
those published by Timàr et al. (10). In 
fact, the aPWV measurement in 50 SSc 
patients showed higher values in limited 
compared to diffuse cutaneous SSc sub-
set, in addition to a direct correlation with 
age and disease duration. By contrast, the 
study by Cheng et al. (13) on 52 SSc pa-
tients revealed a lower arterial compliance 
and a higher stiffness in diffuse SSc. How-
ever, the evaluation was performed using 
real-time B-mode and M-mode images of 
Figure 1 - representation of systemic sclerosis patients divided for 
the cutaneous subsets, namely limited and diffuse (on the left) or limit-
ed, intermediate and diffuse (on the right). Systemic sclerosis patients 
with increased aortic pulse wave velocity are in black.
Figure 2 - representation of systemic sclerosis patients divided for 
the presence of anti-Scl70, anti-centromere (aca), anti-nucleolar 
(anoa), and anti-nuclear (ana) antibodies. Systemic sclerosis pa-
tients with increased aortic pulse wave velocity are in black.
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the motion of the arterial wall and intima-
media thickness evidenced by echography. 
Again, a study by Wan et al., using the an-
kle brachial pressure index in SSc patients, 
suggested a lower median value of the 
index in ACA-positive patients, with in-
creased prevalence of these subjects in the 
symptomatic group presenting intermittent 
claudication or distal amputations (23). 
The increase of aPWV in scleroderma was 
described by Cypiene et al. (8) studying a 
small series of 17 SSc patients compared to 
34 healthy controls. The authors excluded 
individuals presenting diabetes, hypercho-
lesterolemia, hypertension, renal disease, 
and current smoking history; only triglyc-
eride concentration was significantly high-
er in SSc patients than in controls. Overall, 
our findings are consistent with this pre-
vious work. We did not exclude subjects 
presenting some known cardiovascular risk 
factors, but the larger number of patients 
enrolled in our study permitted to evaluate 
also the impact of these factors, as well as 
the difference between patient subgroups 
with/without increased aPWV and the pos-
sible relevance of ongoing therapies. 
The lack of possible correlation between 
aPWV and complicating digital ulcers is 
worthy of attention. One reasonable ex-
planation is that ischemic digital lesions 
may be considered a typical consequence 
of scleroderma microangiopathy, whereas 
increased aPWV is a direct expression of 
large artery involvement, mainly the aorta 
and his branches. Therefore, we can pre-
sume that digital ulcers and arterial stiff-
ness are not clinically correlated, even 
though they may be the consequence of the 
same SSc pathogenetic process. 
In our study, we observed the lack of 
correlation between aPWV increase and 
pulmonary hypertension, restrictive re-
spiratory syndrome as expressed by FVC 
reduction, as well as DLCO decrease. The 
lack of correlation of aPWV with pulmo-
nary hypertension can be explained fol-
lowing the above considerations for pe-
ripheral vascular manifestations; namely, 
by taking into account the vascular dis-
tricts involved characterized by differ-
ent structural and physiological features. 
As regards the lung function texts, par-
ticularly the DLCO, which is an indirect 
functional index of the alveolar oxygen 
exchange, the influence of several fac-
tors, mainly lung fibrosis and pulmonary 
hypertension, have to be considered; con-
sequently, the correlation with aPWV in-
crease seems to be quite improbable.
The aPWV is generally accepted as the 
gold standard measurement of arterial 
stiffness because it is a simple, noninva-
sive, and very reproducible method (14, 
15); indeed, several studies support the 
usefulness of this tool as a good predictor 
of cardiovascular events (24, 25). A recent 
meta-analysis of 17 longitudinal studies 
evaluating 15,877 individuals with aPWV 
for a mean of 7.7 years found that the risk 
of cardiovascular events raises proportion-
ally in a linear-like fashion of more than 
40% for 1 standard deviation of increased 
aPWV (24).
Waveforms are obtained transcutaneously 
with a tonometer over the common carotid 
artery and the femoral artery; aPWV is cal-
culated as the distance (metres) between 
the two recording sites out of the time de-
lay (seconds) measured between the feet 
of the two waveforms. The pressure wave 
features are related to the left ventricular 
contraction strength, to the properties of 
the blood (i.e. viscosity), and to the charac-
teristics of the arterial tree (14, 15). When 
the wave reaches branch points, which are 
areas of turbulence, it is reflected back to 
the heart. So, the final pressure wave is the 
sum of the forward and reflected waves. 
The aPWV measurement focuses on the 
aorta and its first branches, whose walls 
contains elastic fibres in the tunica media; 
these fibres are responsible for the periph-
eral propagation of the pulse that follows 
left ventricular contraction during systole. 
In the case of individuals with stiffness, 
arteries are less compliant, because elas-
tin/collagen ratio is reduced. Therefore, 
the reflected wave returns to left ventricle 
sooner increasing cardiac workload and 
decreasing the pressure support for coro-
nary perfusion (14). For this reason, arte-
rial stiffness is considered a risk factor for 
cardiovascular events and aPWV measure-
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ment affords useful information in patients 
considered with a high cardiovascular risk. 
Indeed, arterial stiffness is a pivotal fea-
ture of the artery involvement in course of 
diseases such as hypertension, diabetes, as 
well as for smoking habit (25). Also age 
has a clear effect on aPWV, since years of 
pulsatile stress lead to fragmentation of 
vascular elastin elements, accumulation of 
load-bearing collagen, and consequently 
vascular calcifications (15). In our study, 
older subjects consistently presented an 
augmented aPWV. However, in SSc pa-
tients aPWV was even higher compared to 
the age-matched controls, suggesting that 
SSc itself may be considered, as well as 
diabetes or hypertension, a cause of arte-
rial stiffness. 
Interestingly, the classical cardiovascular 
risk factors considered, SSc and control 
groups were not homogeneous: control 
subjects showed significantly higher BMI 
and familiarity for cardiovascular events. 
These differences further stress our find-
ings since they should increase the per-
centage of elevated aPWV in controls. 
Obesity, in the absence of the traditional 
cardiovascular risk factors, is associated 
with increased aPWV, while a significant 
weight loss results in its improvement 
(26). On the other hand, SSc patients were 
treated with low-dosage of prednisone, so 
a negative metabolic effect of chronic ste-
roid treatment could be presumable. How-
ever, in the present SSc series no patients 
showed clear steroid-related side-effects, 
possibly due to the short-term and low-
dosage of steroid treatment. Conversely, 
the long-lasting treatment with steroids 
should be considered as a possible wors-
ening co-factor for the arterial damage 
caused by the disease; anyway, the exclu-
sion of SSc patients treated with steroids 
did not alter the statistical difference re-
ported between patients and controls. The 
majority of our patients were treated with 
calcium-channel blockers, able to reduce 
arterial stiffness and to prevent its progres-
sion (27). Therefore, the prevalence of 
aPWV alterations might be somewhat un-
derestimated in the present SSc series due 
to chronic usage of these drugs.
On the whole, our study demonstrated 
a clear-cut prevalence of abnormally in-
creased aPWV in SSc patients compared to 
healthy controls, possibly related to large 
artery alteration due to scleroderma patho-
genetic process. A more pronounced vas-
cular damage is detectable in SSc patients 
with limited scleroderma, serum ACA, 
and/or longer disease duration. One pos-
sible limitation of the present study is the 
size of SSc series, which might reduce the 
statistical significance of aPWV alterations 
among clinico-serological disease subsets. 
The study of larger patients’ series is re-
quired to confirm our preliminary findings. 
n	 REFERENCES
1. Kahaleh MB, LeRoy EC. Autoimmunity and 
vascular involvement in systemic sclerosis 
(SSc). Autoimmunity. 1999; 31: 195-214.
2. Herrick AL. Vascular function in systemic 
sclerosis. Curr Opin Rheumatol. 2000; 12: 
527-33.
3. Wigley FM. Vascular disease in scleroderma. 
Clinic Rev Allerg Immunol. 2009; 36: 150-75.
4. Belch JJ, McSwiggan S, Lau C. Macrovascu-
lar disease in systemic sclerosis: the tip of an 
iceberg? Rheumatology. 2008; 47 (Suppl. 5): 
v16-7.
5. Ho M, Veale D, Eastmond C, et al. Macrov-
ascular disease and systemic sclerosis. Ann 
Rheum Dis. 2000; 59: 39-43.
6. Mok MY, Chiu SS, Lo Y, et al. Coronary 
atherosclerosis using computed tomography 
coronary angiography in patients with sys-
temic sclerosis. Scand J Rheumatol. 2009; 38: 
381-5.
7. Bartoli F, Blagojevic J, Bacci M, et al. Flow-
mediated vasodilation and carotid intima-me-
dia thickness in systemic sclerosis. Ann N Y 
Acad Sci. 2007; 1108: 283-90.
8. Cypiene A, Laucevicius A, Venals A, et al. The 
impact of systemic sclerosis on arterial wall 
stiffness parameters and endothelial function. 
Clin Rheumatol. 2008; 27: 1517-22.
9. Soltész P, Dér H, Kerekes G, et al. A compara-
tive study of arterial stiffness, flow-mediated 
vasodilation of the brachial artery, and the 
thickness of the carotid artery intima-media in 
patients with systemic autoimmune diseases. 
Clin Rheumatol. 2009; 28: 655-62.
10. Timár O, Soltész P, Szamosi S, et al. Increased 
arterial stiffness as the marker of vascular in-
volvement in systemic sclerosis. J Rheumatol. 
2008; 35: 1329-33. 
11. Moyssakis I, Gialafos E, Vassiliou V, et al. 
Aortic stiffness in systemic sclerosis is in-
Reumatismo	6/2012	 367
Original
articlePulse	wave	velocity	in	scleroderma
creased independently of the extent of skin 
involvement. Rheumatology. 2005; 44: 251-4.
12. Park JH, Sung YK, Bae SC, et al. Ulnar artery 
vasculopathy in systemic sclerosis. Rheumatol 
Int. 2009; 29: 1081-6. 
13. Cheng KS, Tiwari A, Boutin A, et al. Carotid 
and femoral arterial wall mechanics in sclero-
derma. Rheumatology. 2003; 42: 1299-305.
14. Hirata K, Kawakami M, Rourke MF. Pulse 
wave analysis and pulse wave velocity - a 
review of blood pressure interpretation 100 
years after Korotkov. Circ J. 2006; 70: 1231-9.
15. DeLoach SS, Townsend RR. Vascular stiff-
ness: its measurement and significance for 
epidemiologic and outcome studies. Clin J Am 
Soc Nephrol. 2008; 3: 184-92.
16. Preliminary criteria for the classification of 
systemic sclerosis (scleroderma). Subcom-
mittee for scleroderma criteria of the Ameri-
can Rheumatism Association Diagnostic and 
Therapeutic Criteria Committee. Arthritis 
Rheum. 1980; 23: 581-90.
17. Lang RM, Bierig M, Devereux RB, et al. Rec-
ommendations for chamber quantification: a 
report from the American Society of Echo-
cardiography‘s Guidelines and Standards 
Committee and the Chamber Quantification 
Writing Group, developed in conjunction 
with the European Association of Echocar-
diography, a branch of the European Society 
of Cardiology. J Am Soc Echocardiogr. 2005; 
18: 1440-63.
18. The Task Force for the Diagnosis and Treat-
ment of Pulmonary Hypertension of the Euro-
pean Society of Cardiology (ESC) and the Eu-
ropean Respiratory Society (ERS), endorsed 
by the International Society of Heart and Lung 
Transplantation (ISHLT). Guidelines for the 
diagnosis and treatment of pulmonary hyper-
tension. Eur Heart J. 2009; 30: 2493-537.
19. LeRoy EC, Black C, Fleischmajer R, et al. 
Scleroderma (systemic sclerosis): classifica-
tion, subsets and pathogenesis. J Rheumatol. 
1988; 15: 202-5.
20. Wigley FM, Wise RA, Miller R, et al. Anticen-
tromere antibody as a predictor of digital isch-
emic loss in patients with systemic sclerosis. 
Arthritis Rheum. 1992; 35: 688-93.
21. Herrick AL, Heaney M, Hollis S, et al. Anti-
cardiolipin, anticentromere and anti-Scl-70 
antibodies in patients with systemic sclerosis 
and severe digital ischaemia. Ann Rheum Dis. 
1994; 53: 540-2.
22. Youssef P, Brama T, Englert H, et al. Limited 
scleroderma is associated with increased prev-
alence of macrovascular disease. J Rheumatol. 
1995; 22: 469-72.
23. Wan MC, Moore T, Hollis S, et al. Ankle 
brachial pressure index in systemic sclerosis: 
influence of disease subtype and centromere 
antibody. Rheumatology. 2001; 40: 1102-5.
24. Vlachopoulos C, Aznaouridis K, Stefanadis 
C. Prediction of cardiovascular events and all-
cause mortality with arterial stiffness: a sys-
tematic review and meta-analysis. J Am Coll 
Cardiol. 2010; 55: 1318-27.
25. Laurent S, Boutouyrie P. Arterial stiffness: 
a new surrogate end point for cardiovascu-
lar disease? J Nephrol. 2007; 20 (Suppl 12): 
S45-50.
26. Rider OJ, Tayal U, Francis JM, et al. The Ef-
fect of Obesity and Weight Loss on Aortic 
Pulse Wave Velocity as Assessed by Mag-
netic Resonance Imaging. Obesity. 2010; 18: 
2311-6.
27. Vaja V, Ochodnicky P, Krenek P, et al. Rapid 
large artery remodeling following the admin-
istration and withdrawal of calcium channel 
blockers in spontaneously hypertensive rats. 
Eur J Pharmacol. 2009; 619: 85-91.
